Anika Therapeutics reported $23.02M in Gross Profit on Sales for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Abbott ABT:US $ 6505M 1225M
Adamas Pharmaceuticals ADMS:US 25.32M 3.88M
Anika Therapeutics ANIK:US $ 23.02M 2.21M
Clovis Oncology CLVS:US $ 28.07M 0.88M
Flexion Therapeutics FLXN:US $ 17.6M 5.6M
Halozyme Therapeutics HALO:US $ 97.24M 16.2M
Insmed INSM:US $ 36.57M 2.04M
Integra Lifesciences IART:US $ 248.25M 1.2M
Johnson & Johnson JNJ:US $ 16088M 343M
Karyopharm Therapeutics KPTI:US $ 37.1M 15.64M
Ligand Pharmaceuticals LGND:US $ 53.39M 0.69M
MacroGenics MGNX:US 14M 16.74M
Merit Medical Systems MMSI:US $ 120.49M 3.64M
Peregrine Pharmaceuticals PPHM:US $ 9.19M 2.2M
Rigel Pharmaceuticals RIGL:US $ 21.39M 4.74M
Stryker SYK:US $ 2757M 45M
Surmodics SRDX:US $ 19.81M 1.04M
Veracyte VCYT:US $ 38.73M 1.09M
Zimmer Biomet Holdings Inc ZBH:US $ 1.34B 102.8M